Skip to main content

Table 2 Summary of adverse events

From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Adverse events

Total (%)

Grade 1 (%)

Grade 2 (%)

Grade 3 (%)

Grade 4 (%)

Hemoglobin

5 (55.6)

3 (33.3)

2 (22.2)

0

0

WBC

2 (22.2)

0

2 (22.2)

0

0

Lymphopenia

3 (33.3)

2 (22.2)

0

1 (11.1)

0

Neutrophil

2 (22.2)

0

2 (22.2)

0

0

Platelet

3 (33.3)

3 (33.3)

0

0

0

Injection site reaction

9 (100)

4 (44.4)

5 (55.6)

0

0